GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Steminent Biotherapeutics Inc (ROCO:7729) » Definitions » Equity-to-Asset

Steminent Biotherapeutics (ROCO:7729) Equity-to-Asset : 0.84 (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Steminent Biotherapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Steminent Biotherapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2024 was NT$422.23 Mil. Steminent Biotherapeutics's Total Assets for the quarter that ended in Jun. 2024 was NT$505.35 Mil.

The historical rank and industry rank for Steminent Biotherapeutics's Equity-to-Asset or its related term are showing as below:

ROCO:7729' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.13   Med: 0.82   Max: 0.87
Current: 0.84

During the past 4 years, the highest Equity to Asset Ratio of Steminent Biotherapeutics was 0.87. The lowest was -0.13. And the median was 0.82.

ROCO:7729's Equity-to-Asset is ranked better than
72.82% of 1512 companies
in the Biotechnology industry
Industry Median: 0.67 vs ROCO:7729: 0.84

Steminent Biotherapeutics Equity-to-Asset Historical Data

The historical data trend for Steminent Biotherapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Steminent Biotherapeutics Equity-to-Asset Chart

Steminent Biotherapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
-0.13 0.87 0.69 0.83

Steminent Biotherapeutics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Equity-to-Asset Get a 7-Day Free Trial - 0.69 0.80 0.83 0.84

Competitive Comparison of Steminent Biotherapeutics's Equity-to-Asset

For the Biotechnology subindustry, Steminent Biotherapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Steminent Biotherapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Steminent Biotherapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Steminent Biotherapeutics's Equity-to-Asset falls into.



Steminent Biotherapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Steminent Biotherapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=492.987/593.876
=0.83

Steminent Biotherapeutics's Equity to Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

Equity to Asset (Q: Jun. 2024 )=Total Stockholders Equity/Total Assets
=422.233/505.349
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Steminent Biotherapeutics  (ROCO:7729) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Steminent Biotherapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Steminent Biotherapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Steminent Biotherapeutics Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
No.16,Wenhu Street, Neihu District, Taipei, TWN, 11445
Steminent Biotherapeutics Inc is a international stem cell biopharmaceutical company which has stable and efficient stem cell platform technology, aiming to develop live cell drugs to treat degenerative diseases as well as acute and life-threatening diseases. With its Stemchymal which is proprietary technology platform generating the standardized, clinical grade, allogeneic stem cells isolated from human adipose tissue. It is operated in strict compliance to regulations of Taiwan, the US, and Japan.

Steminent Biotherapeutics Headlines

No Headlines